ARA-290

ARA-290 is a small peptide derivative of the beta-helix domain of erythropoietin (EPO).  It is a nonhematopoietic peptide designed from the structure of erythropoietin while retaining tissue-protective and anti-inflammatory properties. Preclinical studies show that the ARA-290 peptide offers neuroprotective and pain-relieving effects of EPO in research participants without stimulating red blood cell production. 

In addition to its neuroprotective benefits, ARA-290 has shown efficacy in clinical studies of neuropathy and metabolic control. It has completed phase II trials and is preparing to enter phase III trials for various applications in diabetes and autoimmune sarcoidosis. The peptide is of active interest for its ability to control neuropathic pain and is also under investigation as a potential stimulator of wound repair in chronic diabetes, an immune modulatory drug, and a potential treatment for systemic lupus. 

How Does ARA-290 Work?

ARA-290 (Cibinetide is a synthetic peptide that may exert anti-inflammatory, neuroprotective, and cytoprotective effects without stimulating red blood cell production in subjects. According to research studies, it selectively binds to the innate repair receptor (IRR). This receptor is a heterodimer composed of two parts, EPOR and CD131 (β-common receptor). The IRR becomes more active in response to injury or inflammation. By attaching to this receptor, ARA-290 may reduce inflammation, protect nerve cells, and support tissue healing while avoiding erythropoietic activity in test subjects.

Apart from this, ARA-290 may also reduce pro-inflammatory cytokines while promoting anti-inflammatory signaling. This modulation may help prevent chronic inflammation and tissue damage, particularly in autoimmune and neuropathic conditions. Also, studies have revealed that it may promote nerve regeneration by increasing corneal nerve fiber density and reducing neuropathic pain. 

Properties of ARA-290 Peptide

• Molecular Formula: C51H84N16O21

• Molar Mass: 1257.3 g/mol 

• CAS Number: 1208243-50-8

• Synonyms: cibinetide, PH-BSP 

• PubChem CID: 91810664

Potential Benefits of ARA-290

Some of the potential benefits shown by ARA-290 peptide in research subjects are:

• Repair Muscle Tissue: 

ARA-290 activates the innate repair receptors (IRR), which have been shown to support tissue regeneration and inflammation reduction. Unlike EPO, it does not stimulate red blood cell production but may promote tissue protection and repair in response to injuries. While most studies have focused on nerve repair and inflammation reduction, emerging evidence suggests that ARA-290 may support muscle recovery, particularly by reducing inflammation, oxidative stress, and ischemia damage. [1]

• Reducing Age-Related Side Effects:

Age-related side effects are typically associated with muscle loss, chronic inflammation, metabolic decline, nerve degeneration, and increased risk of chronic diseases. According to scientific research, ARA-290 has been studied for its neuroprotective, anti-inflammatory, and tissue-regenerative properties. Although it does not directly reverse aging, it may mitigate some aging-related conditions by reducing inflammation, promoting nerve repair, and protecting tissue from ischemia and oxidative damage. [2] 

• Chronic Pain Management:

Unlike traditional painkillers, ARA-290 may repair small nerve fibers and modulate immune responses. This makes it a promising option for chronic pain conditions. Investigational studies have shown that it binds to EPOR-CD131, which is only expressed in damaged or inflamed tissues. This selective activation may lead to nerve repair and reduced inflammation. Moreover, ARA-290 has been clinically tested for SNF-related pain relief and showed improvement in both pain reduction and nerve repair. [2]

• Organ and Ischemic Injury Prevention:

Research shows that the ARA-290 may help prevent acute kidney injury by reducing oxidative stress and inflammation in test participants. It has also been shown to prevent Ischemic injury in the brain and heart tissues. Ischemic injury occurs when blood flow is restricted, causing oxygen deprivation and tissue damage. However, evidence supporting these benefits is limited, and more clinical trials are needed. [3] 

Why Choose BehemothLabz to Buy ARA-290 Online?

Are you looking for a renowned vendor to purchase ARA-290 peptide online? BehemothLabz offers quality ARA-290 for sale. 

With a proven track record, we ensure top-quality peptides for research purposes. We also provide detailed information about the product quality control and testing procedures, ensuring the customers are well-informed about the standards each product meets. Besides quality assurance, our products offer highly authentic and reliable research results.

Want to buy ARA-290 online for your research? Place your order now! 

FAQs

What is the best place to buy ARA-290 online?

Behemoth Labz is the best place to buy ARA-290 online. It provides authentic and research-oriented products. 

What is ARA-290 used for?

ARA-290 is a synthetic peptide derived from EPO that may selectively activate the Innate Repair Receptor (IRR). This mechanism allows it to exert anti-inflammatory, tissue-repairing, and neuroprotective effects. 

Are there any known side effects of the ARA-290?

Currently, clinical and preclinical studies have shown that the ARA-290 is well-tolerated with minimal reported side effects. Unlike EPO, it does not stimulate red blood cell production, reducing risks associated with increased hematocrit levels. 

Can ARA-290 be used for conditions other than neuropathic pain?

Yes, research is being carried out to explore the potential benefits of ARA-290 in treating conditions other than neuropathic pain including metabolic disorders and tissue repair, 

Is ARA-290 safe?

Yes, ARA-290 is generally safe for research investigation. However, it is not yet approved for human consumption. 

Is ARA-290 the same as erythropoietin (EPO)?

No, these two products are not the same. While the ARA-290 is derived from EPO, it does not stimulate erythropoiesis, i.e., the production of red blood cells. 

References 

1. van Velzen, Monique, et al. “ARA 290 for treatment of small fiber neuropathy in sarcoidosis.” Expert opinion on investigational drugs 23.4 (2014): 541-550.
2. Swartjes, Maarten, et al. “ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response.” Molecular pain 10 (2014): 1744-8069.
3. Brines, Michael, et al. “ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.” Molecular medicine 20 (2014): 658-666.

Strength	16mg

1st Party COA